These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1684983)

  • 1. The future role and importance of macrolides.
    Ball P
    J Hosp Infect; 1991 Sep; 19 Suppl A():47-59. PubMed ID: 1684983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
    Langtry HD; Brogden RN
    Drugs; 1997 Jun; 53(6):973-1004. PubMed ID: 9179528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.
    Dunn CJ; Barradell LB
    Drugs; 1996 Mar; 51(3):483-505. PubMed ID: 8882383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced-generation macrolides: tissue-directed antibiotics.
    Amsden GW
    Int J Antimicrob Agents; 2001; 18 Suppl 1():S11-5. PubMed ID: 11574189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The macrolides: erythromycin, clarithromycin, and azithromycin.
    Alvarez-Elcoro S; Enzler MJ
    Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA
    Drugs; 2001; 61(4):443-98. PubMed ID: 11324679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ketolides: a critical review.
    Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ
    Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
    Hammerschlag MR; Roblin PM; Bébéar CM
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
    Neu HC; Chick TW
    Chest; 1993 Nov; 104(5):1393-9. PubMed ID: 8222794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological profile of telithromycin, the first ketolide antimicrobial.
    Felmingham D
    Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant respiratory pathogens and extended-spectrum antibiotics.
    Pichichero ME
    Am Fam Physician; 1995 Nov; 52(6):1739-46. PubMed ID: 7484684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host.
    Vergis EN; Yu VL
    Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
    Ferrara AM; Fietta AM
    Drugs Aging; 2004; 21(3):167-86. PubMed ID: 14979735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azithromycin. A review of its use in paediatric infectious diseases.
    Langtry HD; Balfour JA
    Drugs; 1998 Aug; 56(2):273-97. PubMed ID: 9711451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The newer macrolides. Azithromycin and clarithromycin.
    Zuckerman JM; Kaye KM
    Infect Dis Clin North Am; 1995 Sep; 9(3):731-45. PubMed ID: 7490441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
    Carbon C; Poole MD
    J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin in lower respiratory tract infections.
    Lode H; Schaberg T
    Scand J Infect Dis Suppl; 1992; 83():26-33. PubMed ID: 1336893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.